ERBB2 and bone metastasis: In six out of seven patients (86%), both primary tumor and bone metastasis samples showed HER2 staining intensity ≥1, and the intensity score difference between the primary tumor and the respective bone metastasis samples was not more than 1 (Table 2, Figure 6).